<DOC>
	<DOCNO>NCT02345070</DOCNO>
	<brief_summary>Primary Objective : To evaluate , comparison placebo , efficacy 2 dose level SAR156597 administer subcutaneously 52 week lung function patient Idiopathic Pulmonary Fibrosis ( IPF ) . Secondary Objectives : To evaluate efficacy 2 dose level SAR156597 compare placebo IPF disease progression . To evaluate safety 2 dose level SAR156597 compare placebo patient IPF .</brief_summary>
	<brief_title>Efficacy Safety SAR156597 Treatment Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>The total study duration study expect 68 week ( screen period 4 week , treatment period 52 week , 12 week follow ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Inclusion criterion : Adult male female patient . Documented diagnosis IPF accord current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/ American Latin Thoracic Association ( ATS/ERS/JRS/ALAT ) guideline . Signed write informed consent . Exclusion criterion : Age â‰¤40 year . IPF disease diagnosis &gt; 5 year . Forced vital capacity ( FVC ) &lt; 40 % predict value . Carbon monoxide diffuse lung capacity ( DLco ) correct hemoglobin &lt; 30 % predict value . Severe chronic obstructive bronchitis characterize forced expiratory volume 1 second /forced vital capacity ( FEV1/FVC ) &lt; 0.70 . Need 24 hrs oxygen therapy oxygen saturation &lt; 88 % 10 minute breathe ambient air rest . Known diagnosis significant respiratory disorder IPF . Pulmonary artery hypertension require specific treatment . Currently list and/or anticipate list lung transplantation within next 6 month ( active list ) . History vasculitis connective tissue disorder . Known human immunodeficiency virus ( HIV ) chronic viral hepatitis . Patients active tuberculosis incompletely treat latent tuberculosis infection . Use cytotoxic/immunosuppressive agent include limited azathioprine , cyclophosphamide , methotrexate , cyclosporine within 4 week prior screen . Use cytokine modulators ( etanercept , adalimumab , efalizumab , infliximab , golimumab , certolizumab , rituximab ) within 12 week 5 halflives screen ( 24 week rituximab 24 month alefacept ) . Use investigational drug within 1 month screening , 5 halflives , know ( whichever longer ) , within 12 week stem cell therapy . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>